Corvus Pharmaceuticals Confirms Planned Initiation Of Soquelitinib Phase 3 Registrational Clinical Trial In Peripheral T Cell Lymphoma Following Meeting With FDA
Portfolio Pulse from Happy Mohamed
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has confirmed plans to initiate a Phase 3 clinical trial of soquelitinib, its ITK inhibitor product candidate, in relapsed peripheral T cell lymphoma (PTCL) in Q1 2024. The trial is designed to enroll 150 patients and will compare soquelitinib to standard of care chemotherapy. The company is recruiting U.S. and international investigators and anticipates participation from leading academic and private medical centers.
September 06, 2023 | 8:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corvus Pharmaceuticals' announcement of the initiation of a Phase 3 clinical trial for soquelitinib could potentially boost investor confidence in the company's pipeline and future prospects.
The initiation of a Phase 3 clinical trial is a significant milestone in drug development, indicating that the drug has shown promise in earlier trials. This news could potentially boost investor confidence in Corvus Pharmaceuticals' pipeline and future prospects, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100